With its rep on the line, Cel­gene's new­ly-filed safe­ty study spurs fresh wor­ries over fate of ozan­i­mod

Last year
Pharma

A go-go FDA is poised to break the all-time record on new drug ap­provals. Is this the new stan­dard for bio­phar­ma suc­cess?

Last year
Pharma
Special

Glob­al reach: The top 25 bio­phar­ma com­pa­nies in the world

Last year
Special

Genen­tech team does some cut­ting-edge work on a new class of an­tibi­otics — here's why that's im­por­tant

Last year
Bioregnum
R&D

The high-roller club in bio­phar­ma: Who’s pay­ing top-dol­lar for up­fronts? And who are the busiest play­ers at the deal ta­ble?

Last year
Pharma
R&D

Who are the most pro­duc­tive drug de­vel­op­ers in bio­phar­ma? Our top-20 list has lots of sur­pris­es

Last year
R&D
Special

Top 10 pipeline blowups, set­backs and sna­fus in H1 2018

Last year
R&D
Special

Vant com­man­der Ra­maswamy heads back to Nas­daq with a $150M pitch — are in­vestors ready to for­give Ax­o­vant?

Last year
IPOs

12 top Chi­na VCs you need to know who are mak­ing a transpa­cif­ic splash (Part 2)

Last year
China
Special

RIP XTu­it: Great brains, hot tar­get and vet CEO Deb­o­rah Dun­sire in charge couldn’t stop this biotech from go­ing down

Last year
Startups
Venture

What you need to know about this record-set­ting biotech IPO burst as 5 more crash the par­ty look­ing for $547M

Last year
IPOs

The 2-tri­al hur­dle for drug ap­provals is steadi­ly los­ing ground. Are we de­valu­ing the in­dus­try's R&D gold stan­dard?

Last year
Bioregnum

Where does the sci­ence come from? The top 20 NIH-fund­ed in­sti­tu­tions in 2017

Last year
R&D

The good, the bad and the ug­ly for the top 15 spenders in the glob­al drug R&D busi­ness: 2018

Last year
R&D
Special

Bris­tol-My­ers of­fers some ea­ger­ly await­ed Check­mate-227 re­sults, but they're not chang­ing med­ical prac­tice -- yet

Last year
R&D

What are the top 10 cor­po­rate VCs in bio­phar­ma to­day? And what do they want to fund — or steer clear of?

Last year
Venture

Where the mon­ey is: Top 100 VCs in­vest­ing in US biotechs dur­ing 2017

Last year
Startups
Venture

The class of 2017's win­ners and losers: A year of 'non­stop sci­en­tif­ic achieve­ments' rais­es trou­bling is­sues

Last year
Pharma

Bio­phar­ma's top 10 over­seas cash hoards. And what kind of M&A spree would $171B buy?

Last year
Deals

The top 10 hit pa­rade of bio­phar­ma li­cens­ing deals for 2014-2017

Last year
Pharma

Who are the top 10 play­ers that dom­i­nate the can­cer drug mar­ket? And who's grow­ing fastest?

3 years ago
Pharma
R&D

In­sid­ers: The top 20 rare dis­ease spe­cial­ists spot­light key biotech trends be­hind the boom

3 years ago

R&D trend #5: The top ex­ecs in biotech are rid­ing a boom — but there’s one big step left

3 years ago

Top trend #4: We’re com­ing to a tip­ping point on can­cer R&D, and it may not be pret­ty

3 years ago
R&D
First page Previous page 1234 Next page Last page